Global Toxoid Vaccine Market Report 2022 to 2028: Featuring Astellas Pharma, Bharat Biotech, Novartis and Pfizer Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--Dec 5, 2022--

The "Global Toxoid Vaccine Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

The global toxoid vaccine market is anticipated to grow at a substantial CAGR of 4.5% during the forecast period. Toxoid vaccines use harmful products or toxins developed by the germ that causes a disease.

Companies Mentioned

• Astrazeneca PLC
• Astellas Pharma Inc.
• BAYER AG
• Bharat Biotech
• CEVA Sante Animale S.A.
• Emergent Biosolutions Inc.
• GlaxoSmithKline PLC
• GRIFOLS S.A.
• Merck & Co. Inc. (Merck Sharp & Dohme Corp.)
• Novartis AG
• Panacea Biotec Ltd.
• Paxvax Inc.
• Pfizer Inc.
• Sanofi Pasteur Inc.
• Sinovac Biotech Ltd.
• The Serum Institute Of India Limited
• Virbac
• Valeant Pharmaceuticals
• ZOETIS

These vaccines create immunity to the parts of the germ, which further divert the immune response to target the toxin instead of the whole germ. The primary factor contributing to the growth of the market includes the rising prevalence of tetanus and diphtheria along with clinical trials of vaccines. According to Clinicaltrials.gov, in 2020, a title published named Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects is under the phase-2clinical trials.

The global toxoid vaccine market is segmented based on disease, composition, form, and end-user. Based on the disease, the market is sub-segmented into tetanus, diphtheria, and pertussis. Based on the composition, the market is sub-segmented into monovalent tetanus toxoid (TT), tetanus and pertussis (DTaP), diphtheria and tetanus (DT), tetanus and diphtheria (TD), and tetanus, diphtheria, and pertussis (TDAP).

Based on the form, the toxoid vaccine market is further augmented into quadrivalent, pentavalent, and hexavalent. Further, based on the end-user, the market is sub-segmented into hospitals, clinics (veterinary), and government. Among the composition, the DTaP segment is expected to hold a considerable share in the market across the globe, owing to the rising various government initiatives to reduce and eradicate cases of these diseases.

According to the World Health Organization (WHO) reports released in 2021, as of November 2020, five countries in America had reported a total of 56 confirmed cases of diphtheria, with 16 deaths. For instance, in June 2022, the National Health Mission replaced the TT vaccine with the DTaP vaccine in UIP to limit the continuously declining immunity against diphtheria in the population aged 60 years and above.

Geographically, the global toxoid vaccine market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region is expected to hold a prominent market share in the global toxoid vaccine market. Owing to the rising incidences of tetanus and diphtheria along with higher cost, coverage, and adoption of vaccines in the region. According to the WHO report published in May 2019, around 56 cases of tetanus and diphtheria were reported in 2019, out of which the laboratory-confirmed 6 cases and 1 death.

The Report Covers

• Comprehensive research methodology of the global toxoid vaccine market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the global toxoid vaccine market.
• Insights about market determinants that are stimulating the global toxoid vaccine market.
• Detailed and extensive market segments with the regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis

3.1.1. Overview

3.1.2. Financial Analysis

3.1.3. SWOT Analysis

3.1.4. Recent Developments

3.2. Key Strategy Analysis

3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

4.1. Global Toxoid Vaccine Market by Disease

4.1.1. Tetanus

4.1.2. Diphtheria

4.1.3. Pertussis

4.2. Global Toxoid Vaccine Market by Composition

4.2.1. Monovalent Tetanus Toxoid (TT)

4.2.2. Diphtheria, Tetanus, and Pertussis (DTaP)

4.2.3. Diphtheria and Tetanus (DT)

4.2.4. Tetanus and Diphtheria (TD)

4.2.5. Tetanus, Diphtheria, and Pertussis (TDAP)

4.3. Global Toxoid Vaccine Market by Form

4.3.1. Quadrivalent

4.3.2. Pentavalent

4.3.3. Hexavalent

4.4. Global Toxoid Vaccine Market by End-User

4.4.1. Hospitals

4.4.2. Clinics(Veterinary)

4.4.3. Government

5. Regional Analysis

6. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/pbnbzp

View source version on businesswire.com:https://www.businesswire.com/news/home/20221205005367/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2022.